| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Tanii, A Okayama, A Yamatodani, M Hayashi, K Hashimot. Alterations in the metabolism of serotonin and dopamine in the mouse brain following a single administration of allylnitrile, which induces long-term dyskinesia. Toxicology letters. vol 58. issue 3. 1991-12-30. PMID:1720266. |
alterations in the metabolism of serotonin and dopamine in the mouse brain following a single administration of allylnitrile, which induces long-term dyskinesia. |
1991-12-30 |
2023-08-11 |
mouse |
| H Tanii, A Okayama, A Yamatodani, M Hayashi, K Hashimot. Alterations in the metabolism of serotonin and dopamine in the mouse brain following a single administration of allylnitrile, which induces long-term dyskinesia. Toxicology letters. vol 58. issue 3. 1991-12-30. PMID:1720266. |
the effects of allylnitrile (aln), which induces a long-term dyskinesia in mice, on the metabolism of serotonin (5-ht) and dopamine (da) were studied after a single administration. |
1991-12-30 |
2023-08-11 |
mouse |
| W P Spooren, H J Groenewegen, A R Cool. Subregions of the caudate nucleus and their in- and output channels in oro-facial dyskinesia: a behavioural and retrograde tracing study in the cat. Brain research. vol 539. issue 1. 1991-05-22. PMID:1707740. |
stimulation of dopamine receptors within the r-crm by dopamine or dpi are known to elicit oro-facial dyskinesia (ofd), i.e. |
1991-05-22 |
2023-08-11 |
cat |
| C N Karso. Blinking. Bulletin de la Societe belge d'ophtalmologie. vol 237. 1990-12-31. PMID:2486118. |
in the former illness, reduced blink rate signifies a worsening of the illness and a significant increase in blink rate in patients treated with dopamine agonist may be a harbinger of agonist-induced dyskinesia. |
1990-12-31 |
2023-08-11 |
human |
| H Tanii, M Hayashi, K Hashimot. Alterations in the metabolism of serotonin and dopamine in the central nervous system of mice displaying a persistent dyskinesia due to crotononitrile or 2-pentenenitrile. Archives of toxicology. vol 64. issue 3. 1990-08-23. PMID:2372234. |
alterations in the metabolism of serotonin and dopamine in the central nervous system of mice displaying a persistent dyskinesia due to crotononitrile or 2-pentenenitrile. |
1990-08-23 |
2023-08-11 |
mouse |
| T Nishikawa, S Yamada, A Tsuda, M Tanaka, I Koga, Y Uchid. Chronic treatment with talipexole dihydrochloride on abnormal involuntary movement in humans. Clinical neuropharmacology. vol 13. issue 3. 1990-07-27. PMID:1694103. |
two cases of severe dystonia and dyskinesia were treated with talipexole, a dopamine autoreceptor agonist, and the metabolites of dopamine, norepinephrine, and serotonin in cerebrospinal fluid (csf) were determined. |
1990-07-27 |
2023-08-11 |
Not clear |
| P Hantraye, D Riche, M Maziere, O Isacso. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Experimental neurology. vol 108. issue 2. 1990-06-12. PMID:2139853. |
since the behavioral observations following excitotoxic caudate-putamen damage parallel symptoms in hd patients given dopamine stimulatory drugs, a hypothesis is presented for the observed abnormal movements suggesting that the cp lesions reduce movement thresholds while the activation of dopaminoceptive regions induces dyskinesias. |
1990-06-12 |
2023-08-11 |
Not clear |
| A R Crossma. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement disorders : official journal of the Movement Disorder Society. vol 5. issue 2. 1990-05-24. PMID:1970120. |
a hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in parkinson's disease: implications for future strategies in treatment. |
1990-05-24 |
2023-08-11 |
human |
| A R Crossma. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement disorders : official journal of the Movement Disorder Society. vol 5. issue 2. 1990-05-24. PMID:1970120. |
long-term treatment of human parkinson's disease with levodopa or dopamine agonists is often complicated by the appearance of abnormal involuntary movements (dyskinesias) that are extremely difficult to control. |
1990-05-24 |
2023-08-11 |
human |
| A R Crossma. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement disorders : official journal of the Movement Disorder Society. vol 5. issue 2. 1990-05-24. PMID:1970120. |
a hypothesis is set forth on the neural mechanisms that mediate levodopa- or dopamine agonist-induced dyskinesia (in particular chorea) as a side effect of the treatment of parkinsonism. |
1990-05-24 |
2023-08-11 |
human |
| J M Cedarbau. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease. Neurologic clinics. vol 8. issue 1. 1990-05-09. PMID:2181267. |
dyskinesias may be considered a secondary pharmacodynamic consequence of such pharmacokinetically induced oscillations in brain dopamine levels. |
1990-05-09 |
2023-08-11 |
Not clear |
| J Gerlach, D E Case. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Progress in neuro-psychopharmacology & biological psychiatry. vol 14. issue 1. 1990-03-05. PMID:1967845. |
nine cebus monkeys, 6 with mild spontaneous oral dyskinesia (tongue protrusions), were tested with two dopamine d2 antagonists, remoxipride (a new substituted benzamide) and haloperidol, and with two dopamine agonists, methylphenidate and apomorphine. |
1990-03-05 |
2023-08-11 |
human |
| T N Chase, F Baronti, G Fabbrini, I J Heuser, J L Juncos, M M Mouradia. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology. vol 39. issue 11 Suppl 2. 1990-01-04. PMID:2685653. |
the appearance of peak-dose dyskinesias and complex, random motor fluctuations of the on-off type, on the other hand, may signal secondary postjunctional changes arising as a consequence of chronic intermittent excitation of postsynaptic dopamine receptors that are normally tonically stimulated. |
1990-01-04 |
2023-08-11 |
Not clear |
| T N Chase, F Baronti, G Fabbrini, I J Heuser, J L Juncos, M M Mouradia. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology. vol 39. issue 11 Suppl 2. 1990-01-04. PMID:2685653. |
it is thus tempting to speculate that the early and continuing treatment of parkinson's disease with compounds providing a relatively constant level of central dopamine stimulation will preclude wearing-off phenomena and mitigate on-off fluctuations and severe dyskinesias. |
1990-01-04 |
2023-08-11 |
Not clear |
| C E Clarke, S Boyce, R G Robertson, M A Sambrook, A R Crossma. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Journal of the neurological sciences. vol 90. issue 3. 1989-07-31. PMID:2786926. |
levodopa and the selective d-2 and d-1 dopamine agonists ly-171555 and skf 38393 also reversed parkinsonian features and produced contralateral rotation and peak-dose dyskinesia. |
1989-07-31 |
2023-08-11 |
monkey |
| J M Liebman, S C Gerhardt, R Gerbe. Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology. vol 97. issue 4. 1989-06-27. PMID:2524857. |
although ritanserin is a potent 5-ht2 antagonist with very weak dopamine antagonist properties, this drug did not antagonize dyskinesias but induced them when administered at a high dose (30 mg/kg). |
1989-06-27 |
2023-08-11 |
monkey |
| J M Liebman, S C Gerhardt, R Gerbe. Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology. vol 97. issue 4. 1989-06-27. PMID:2524857. |
buspirone induced dyskinesias and blocked apomorphine-induced climbing, supporting prior reports that it has dopamine antagonist effects. |
1989-06-27 |
2023-08-11 |
monkey |
| J M Liebman, S C Gerhardt, R Gerbe. Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology. vol 97. issue 4. 1989-06-27. PMID:2524857. |
gepirone, a 5-ht1a agonist with less marked dopamine antagonist properties, induced dyskinesias in only one of six monkeys at 30 mg/kg and did not block haloperidol-induced dyskinesias. |
1989-06-27 |
2023-08-11 |
monkey |
| J M Liebman, S C Gerhardt, R Gerbe. Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology. vol 97. issue 4. 1989-06-27. PMID:2524857. |
tonic inhibition of brain extrapyramidal dopamine systems by serotonin systems does not appear to characterize neuroleptic-related dyskinesias in squirrel monkeys. |
1989-06-27 |
2023-08-11 |
monkey |
| P Seeman, N H Bzowej, H C Guan, C Bergeron, L E Becker, G P Reynolds, E D Bird, P Riederer, K Jellinger, S Watanab. Human brain dopamine receptors in children and aging adults. Synapse (New York, N.Y.). vol 1. issue 5. 1989-02-23. PMID:3505371. |
since spontaneous oral dyskinesias are more prevalent in the elderly, and since these movements may be controlled by the balance of brain dopamine d1 and d2 dopamine receptors, we measured the densities of these receptors in 247 postmortem brain striata. |
1989-02-23 |
2023-08-11 |
human |